Get the Stockscreener App
1.945
0.26%
-0.005
Omniab Inc stock is traded at $1.945, with a volume of 236.51K.
It is down -0.26% in the last 24 hours and up +36.49% over the past month.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
See More
Previous Close:
$1.95
Open:
$2
24h Volume:
236.51K
Relative Volume:
0.46
Market Cap:
$279.99M
Revenue:
$34.16M
Net Income/Loss:
$-50.62M
P/E Ratio:
-3.8287
EPS:
-0.508
Net Cash Flow:
$703.00K
1W Performance:
+7.46%
1M Performance:
+36.49%
6M Performance:
+40.94%
1Y Performance:
-49.74%
1-Day Range:
$1.92
$2.04
1-Week Range:
$1.69
$2.04
52-Week Range:
$1.22
$4.17
Omniab Inc Stock (OABI) Company Profile
Name
Omniab Inc
Sector
Industry
Phone
510-250-7800
Address
5980 HORTON STREET, EMERYVILLE
Compare OABI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
1.945 | 283.59M | 34.16M | -50.62M | 703.00K | -0.508 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.49 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.28 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.21 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
898.86 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.53 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-21-23 | Initiated | The Benchmark Company | Buy |
| Apr-13-23 | Initiated | Craig Hallum | Buy |
| Feb-22-23 | Initiated | Cowen | Outperform |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Nov-29-22 | Initiated | SVB Leerink | Outperform |
| Nov-28-22 | Initiated | Stifel | Buy |
View All
Omniab Inc Stock (OABI) Latest News
Can OmniAb Inc. Equity Warrant stock continue upward trendPortfolio Value Summary & AI Enhanced Market Trend Forecasts - Newser
Will OmniAb Inc. stock outperform value stocks2025 Market Outlook & Reliable Breakout Forecasts - Newser
Comparing Wellgistics Health (NASDAQ:WGRX) and OmniAb (NASDAQ:OABI) - Defense World
OmniAb to Hold OmniUltra Virtual Investor Event on December 15 - Business Wire
Is OmniAb Inc. stock overvalued by current metricsFed Meeting & Real-Time Sentiment Analysis - Newser
Why OmniAb Inc. Equity Warrant stock attracts high net worth investorsBear Alert & Momentum Based Trading Ideas - Newser
Is OmniAb Inc. stock cheap compared to fundamentalsInsider Buying & Weekly Watchlist for Consistent Profits - Newser
Why retail investors pile into OmniAb Inc. Equity Warrant stockTake Profit & Safe Capital Growth Stock Tips - moha.gov.vn
Is OmniAb Inc. stock attractive for long term wealth buildingJuly 2025 Rallies & Entry Point Strategy Guides - BỘ NỘI VỤ
What analysts say about OmniAb Inc stockPortfolio Diversification Tips & Rapid Portfolio Appreciation - earlytimes.in
OmniAb, Inc. (OABI) -5.5% in After-hours: Shares Slide Amidst Routine Trading - Stocks Telegraph
OmniAb Inc (OABI) looking to reclaim success with recent performance - Setenews
OmniAb outlines $18M–$22M 2025 revenue guidance while launching OmniUltra and expanding xPloration platform - MSN
OmniAb, Inc. (OABI) Presents at Jefferies London Healthcare Conference 2025Slideshow - Seeking Alpha
Detecting price anomalies in OmniAb Inc. Equity Warrant with AITrade Volume Report & Consistent Profit Focused Trading Strategies - newser.com
Will OmniAb Inc. stock benefit from upcoming earnings reportsQuarterly Profit Summary & Expert Verified Movement Alerts - newser.com
Why OmniAb Inc. stock remains on watchlistsTrend Reversal & Entry and Exit Point Strategies - newser.com
Visual trend scoring systems applied to OmniAb Inc.Market Sentiment Report & Daily Momentum Trading Reports - newser.com
OmniAb Inc. stock outlook for YEARQuarterly Trade Summary & Fast Moving Stock Watchlists - newser.com
Developing predictive dashboards with OmniAb Inc. dataJuly 2025 Spike Watch & Technical Pattern Based Buy Signals - newser.com
Momentum divergence signals in OmniAb Inc. chart2025 Volume Leaders & Safe Capital Growth Trade Ideas - newser.com
Best data tools to analyze OmniAb Inc. stockWeekly Trade Review & Daily Chart Pattern Signals - newser.com
Should you wait for a breakout in OmniAb Inc.Weekly Earnings Recap & AI Enhanced Trading Signals - newser.com
How sustainable is OmniAb Inc. Equity Warrant stock dividend payoutJuly 2025 Analyst Calls & Safe Entry Point Alerts - newser.com
OmniAb (OABI) Price Target Decreased by 13.73% to 7.48 - MSN
Chart based analysis of OmniAb Inc. trendsDollar Strength & Short-Term Trading Alerts - newser.com
How to forecast OmniAb Inc. trends using time seriesEarnings Growth Report & Expert-Curated Trade Recommendations - newser.com
Stocks of OmniAb Inc (OABI) are poised to climb above their peers - Setenews
OmniAb CEO emphasizes discovery platform at Jefferies Conference - Traders Union
Is OmniAb Inc. Equity Warrant stock a defensive play in 2025July 2025 Pullbacks & Free Safe Capital Growth Stock Tips - newser.com
How OmniAb Inc. stock trades during market volatilityJuly 2025 Opening Moves & Fast Gaining Stock Reports - newser.com
What earnings revisions data tells us about OmniAb Inc.2025 Institutional Moves & High Yield Stock Recommendations - newser.com
Will OmniAb Inc. Equity Warrant stock gain from government policies2025 Top Decliners & Proven Capital Preservation Methods - newser.com
OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors - BioSpace
OmniAb partners with ArrowMark and Viking for antibody discovery - Traders Union
OmniAb enters in technology license and services agreement for antibody discovery with a newly-formed incubated company of Arrowmark Partners and Viking Global Investors - MarketScreener
OmniAb Inc. Equity Warrant’s volatility index tracking explained2025 EndofYear Setup & Technical Confirmation Alerts - newser.com
What analysts say about OmniAb Inc Equity Warrant stockVolume Profile Analysis & Options Trading Analysis Tools - earlytimes.in
OmniAb Inc. (OABI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Full technical analysis of OmniAb Inc. Equity Warrant stockQuarterly Trade Report & Technical Entry and Exit Tips - newser.com
Exit strategy if you’re trapped in OmniAb Inc. Equity WarrantQuarterly Performance Summary & Verified Stock Trade Ideas - newser.com
Omniab Inc Stock (OABI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Omniab Inc Stock (OABI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HIGGINS JOHN L | Director |
Nov 06 '25 |
Buy |
1.41 |
36,223 |
51,074 |
2,888,110 |
| Cochran Jennifer R. | Director |
May 15 '25 |
Buy |
1.52 |
30,000 |
45,600 |
145,274 |
| Love Steven | Director |
May 14 '25 |
Buy |
1.46 |
25,000 |
36,500 |
38,333 |
| HIGGINS JOHN L | Director |
May 12 '25 |
Buy |
1.44 |
65,000 |
93,600 |
2,831,887 |
| FOEHR MATTHEW W | President and CEO |
Apr 07 '25 |
Option Exercise |
0.00 |
36,458 |
0 |
3,815,618 |
| FOEHR MATTHEW W | President and CEO |
Apr 07 '25 |
Sale |
2.00 |
19,382 |
38,764 |
3,796,236 |
| Berkman Charles S | Chief Legal Officer |
Apr 07 '25 |
Option Exercise |
0.00 |
13,542 |
0 |
370,418 |
| Berkman Charles S | Chief Legal Officer |
Apr 07 '25 |
Sale |
2.00 |
7,206 |
14,412 |
363,212 |
| GUSTAFSON KURT A | Executive VP, Finance and CFO |
Apr 07 '25 |
Option Exercise |
0.00 |
13,542 |
0 |
231,034 |
| GUSTAFSON KURT A | Executive VP, Finance and CFO |
Apr 07 '25 |
Sale |
2.00 |
7,206 |
14,412 |
223,828 |
0.82%
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):